AU2001288374A1 - Substituted oxindole derivatives as tyrosine kinase inhibitors - Google Patents

Substituted oxindole derivatives as tyrosine kinase inhibitors

Info

Publication number
AU2001288374A1
AU2001288374A1 AU2001288374A AU8837401A AU2001288374A1 AU 2001288374 A1 AU2001288374 A1 AU 2001288374A1 AU 2001288374 A AU2001288374 A AU 2001288374A AU 8837401 A AU8837401 A AU 8837401A AU 2001288374 A1 AU2001288374 A1 AU 2001288374A1
Authority
AU
Australia
Prior art keywords
tyrosine kinase
kinase inhibitors
oxindole derivatives
substituted oxindole
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288374A
Other languages
English (en)
Inventor
Lee Frederick Kuyper
Karen Elizabeth Lackey
Iii Edgar Raymond Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001288374A1 publication Critical patent/AU2001288374A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001288374A 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors Abandoned AU2001288374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23005000P 2000-09-01 2000-09-01
US60230050 2000-09-01
PCT/US2001/026423 WO2002020479A1 (en) 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001288374A1 true AU2001288374A1 (en) 2002-03-22

Family

ID=22863755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288374A Abandoned AU2001288374A1 (en) 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors

Country Status (5)

Country Link
US (2) US7071217B2 (enExample)
EP (1) EP1339680A1 (enExample)
JP (1) JP2004517049A (enExample)
AU (1) AU2001288374A1 (enExample)
WO (1) WO2002020479A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001288374A1 (en) * 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US20030225152A1 (en) * 2001-09-27 2003-12-04 Andrews Steven W. 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (en) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
EP2270048B1 (en) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) * 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
PL2383268T3 (pl) 2005-02-04 2016-02-29 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007123269A1 (ja) 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
DK2044084T3 (en) 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
CN117624014A (zh) * 2022-11-02 2024-03-01 徐诺药业(南京)有限公司 3-(吲哚氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
AU2024238259A1 (en) 2023-03-17 2025-08-21 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6269086B1 (en) * 1998-02-27 2001-07-31 Legerity, Inc. Arrangement and method for selectable time/frequency division multiplex communication
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) * 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6498176B1 (en) * 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
US6620818B1 (en) * 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
AU2001288374A1 (en) * 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
ES2275021T3 (es) 2001-09-27 2007-06-01 Smithkline Beecham Corporation Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.

Also Published As

Publication number Publication date
US7338966B2 (en) 2008-03-04
WO2002020479A1 (en) 2002-03-14
US7071217B2 (en) 2006-07-04
JP2004517049A (ja) 2004-06-10
US20030195234A1 (en) 2003-10-16
EP1339680A1 (en) 2003-09-03
US20050228025A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AP2003002781A0 (en) Quinolinone derivatives as tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
IL182428A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
AU2003299651A1 (en) Tyrosine kinase inhibitors
AU2004272348A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AU2003233455A1 (en) Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU3770000A (en) Indolinone compounds as kinase inhibitors
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
AU2003298942A1 (en) Tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU8664701A (en) Oxindole derivatives
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
AU2001293869A1 (en) Butenolide and pentenolide derivatives as kinase inhibitors